Baxalta sues Chugai over hemophilia A drug patent
Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has revealed that a lawsuit was filed against the company at the Tokyo District Court by US biotechnology firm Baxalta (NYSE: BXLT).
It is alleged by Baxalta that the new drug candidate under development by Chugai, which is majority owned by Swiss pharma giant Roche (ROG: SIX), for the treatment of hemophilia A, emicizumab (development code: ACE910), is infringing one of its patent (patent number 4313531) and thus it filed for an injunction against manufacture, usage, transfer, exportation, and offer of any transfer regarding emicizumab, and requested cessation.
ACE910, currently in late-stage clinical trials by Roche and Chugai, is a double-headed (bispecific) antibody which simultaneously binds to both Factor IXa and Factor X and mimics the effect of Factor VII, the usual treatment for hemophilia A.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze